Hirigoyenberry-Lanson Named CMO at EOS

The 2D/3D pioneers at EOS imaging have announced the appointment of Fabienne Hirigoyenberry-Lanson, Ph.D., as the company’s first Chief Medical Officer. Dr. Hirigoyenberry-Lanson has 22 years of extensive experience of the medical device industry.

Prior to joining EOS imaging, Dr. Hirigoyenberry-Lanson was vice president of Global Medical Affairs at Accuray Inc., a radiation oncology company, where she led clinical and key opinion leader programs to support and sustain market growth. Prior to Accuray, she held several positions in medical device companies and major clinical research organizations. She attended the University of Science of Bordeaux (France) and received her Ph.D. in biology in 1991.

Dr. Hirigoyenberry-Lanson commented in the January 8, 2014 news release, “EOS has developed a compelling new 2D/3D imaging option for orthopaedic treatment, which provides significant benefits to patients, physicians, hospitals and payors by helping to improve diagnosis and outcomes for orthopaedic patients. I look forward to further expanding the company’s clinical and medical affairs to support increased adoption of the EOS system.”

Marie Meynadier, CEO of EOS imaging, said, “We are pleased to welcome Dr. Hirigoyenberry-Lanson to the EOS team. She has a proven track record in the medical device industry, including relevant experience with capital equipment and software driven systems. Her leadership will further enhance our clinical and medical affairs programs as we work to increase awareness and adoption of our unique low-dose, full-body 2D/3D imaging technology for orthopaedics.”

Dr. Hirigoyenberry-Lanson told OTW, “The EOS system has already become an indispensable imaging tool for many thought-leading orthopedic surgeons and institutions around the world. I will focus on strengthening the company’s relationships with these customers in order to drive awareness of the benefits of the EOS system among their peers, along with forming new relationships with additional leaders in the space. I will work closely with these customers to aid in the collection of clinical data supporting the use of the EOS system in terms of improved treatment planning and significantly reduced radiation exposure. On the development front, I expect to play a key role in securing customer input as we integrate the OneFit Medical planning software and patient-specific cutting guide business into the EOS product family.”